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A B S T R A C T
Inflammasome plays a critical role in diverse inflammatory disorders, including cancers and Alzheimer's disease.
It is induced by various pathogenic insults and activates caspase-1, a hallmark executor of inflammasome. Here,
we developed an activatable fluorescence probe for visualization of active caspase-1. This caspase-1 probe is
biocompatible, efficiently delivered into cells and tissues, and specifically emits fluorescence upon caspase-1
activation as assessed in in vitro and in vivo models of inflammatory conditions. We demonstrated efficient in vivo
imaging of caspase-1 activation in early stages of various inflammatory conditions of mice models, including
endotoxin shock, inflammatory bowel disorder, transplanted cancer, and Alzheimer's disease. Notably, the
caspase-1 probe enables detection of neuroinflammation in vivo two months earlier than cognitive impairments
occur in Alzheimer's disease model. We detected significant fluorescence emitted from inflamed sites, as well as
their draining lymph nodes, by macroscopic imaging analysis within 30min after systemic injection of the probe.
This novel synthetic probe could be applied for efficient and rapid detection of caspase-1 activity in a spatio-
temporal way by non-invasive imaging.
1. Introduction
The inflammasome is a multi-protein intracellular complex that
responds to pathogens and sterile stressors via detection of pathogen-
associated molecular patterns (PAMPs) and danger-associated mole-
cular patterns (DAMPs) [1–3]. Upon activation, it induces expression of
highly pro-inflammatory cytokines, including interleukin-1β (IL-1β)
and IL-18, as well the pathway for a proinflammatory form of regulated
cell death, pyroptosis. In detail, this molecular machine comprises of a
receptor that senses PAMPs and/or DAMPs, an adaptor molecule known
as ASC (apoptosis-associated speck-like protein containing a caspase
activation and recruitment domain), and a zymogen procaspase-1 [3].
Recognition of exogenous and/or endogenous stimuli generated by
physiological and pathogenic stresses nucleates ASC to form discrete
foci, or specks, within the activated cell. Caspase-1 is then recruited and
undergoes autocatalytic cleavage to produce active caspase-1. The ac-
tive subunits of caspase-1 can proteolytically process cytokines, IL-1β
and IL-18, to be secreted and trigger pyroptosis through cleavage of
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Gasdermin D [4,5]. Even though multiple molecular sensors, including
NOD-like receptor (NLR) family members, are involved in initiating the
inflammasome activation pathway, activated caspase-1 is a hallmark
executor of this pathway [3,6,7]. Recent advances highlight the in-
volvement of this molecular sentinel with fundamental immunological
processes and its functional importance in maintaining homeostasis of
diverse biological functions [3]. In addition, dysregulation of in-
flammasome is associated with the initiation and progression of a
number of inflammatory syndromes with a high impact on public
health, such as metabolic disorders, cancers, neurodegenerative dis-
eases, as well as microbial infections [8–11]. Therefore, development of
promising therapeutics that target inflammasome activity in various
inflammatory diseases has attracted considerable attention in recent
years [8,12–14].
Detection of inflammasome activation in vitro and in vivo may also
provide enormous advantages for mechanistic studies, diagnosis, drug
discovery, and therapeutic monitoring in inflammatory disorders, given
its wide and significant role in innate immune response, shaping
adaptive immunity, and clearance of pathogenic insults [8,12]. How-
ever, the absence of in vivo monitoring techniques has limited our un-
derstanding of the location and timing of inflammasome activity at the
tissue or organism level. Only a few recent studies have established an
in vivo reporter system to visualize inflammasome activation in real-
time and have just started to dissect its influence on the immune system
[15–17]. For example, a recent study using a live ASC reporter in ge-
netically-modified zebrafish showed that a toxic stimulus triggered ASC
speck formation and rapid pyroptosis in keratinocytes in vivo, and that
macrophages engulfed and digested the speck-containing, pyroptotic
debris [17]. This in vivo imaging demonstration of ASC speck formation
by keratinocytes in response to inflammatory conditions and sub-
sequent pyroptosis, underscores the relevance of inflammasome sig-
naling in epithelia [17]. In addition, another study generated chimeric
mice expressing ASC-GFP in hematopoietic stem cells to visualize the
spatiotemporal dynamics of inflammasome activation in vivo [15]. They
found that transient inflammasome activation in subcapsular sinus
macrophages in draining lymph node is functionally associated with an
influx of inflammatory cells and an increase in the magnitude of T cell
response upon local vaccinia virus infection [15]. Nevertheless, all
these currently available imaging techniques only target ASC and re-
quires genetic modification of cells or organisms to visualize in vivo
dynamics of inflammasome activation. Therefore, quantitative analysis
of inflammation activation in vivo is technically limited and requires
microscopic access to the target cells and tissues for visualization of
ASC speck formation. Targeting the enzymatic activity of caspase-1 is
an alternative since caspase-1 is a hallmark cysteine protease activated
by all the inflammasome pathways [4]. However, current methods
measuring caspase-1 activity generally require cellular lysis or genetic
modification, thereby have limited direct application in vivo [15,18].
In this study, we developed a novel fluorescent probe which can
emit near infrared (NIR) radiation upon specific cleavage by active
caspase-1 and applied it as imaging sensor for inflammasome activa-
tion. In vivo applicability of the caspase-1 sensor was examined in
various acute and chronic inflammatory disorders, including endotoxin
stimulation, inflammatory bowel disease (IBD), grafted cancer, and
Alzheimer's disease (AD), via non-invasive fluorescence imaging. Our
results show that the synthetic fluorescent probe enables quantitative
analysis of spatiotemporal dynamics in vivo inflammasome activation
without invasive treatment. Furthermore, efficient visualization of in-
flammasome activity enable early detection of inflammatory sites and
their draining lymph nodes before manifestation of systemic signs or
symptoms in the specific disorders. Therefore, our probe system could
provide a novel platform to detect in vivo dynamics of active in-
flammasome for diagnosis, drug discovery, and therapeutic monitoring
in various inflammatory conditions.
2. Materials and methods
2.1. Reagents and antibodies
Cy5.5 (Flamma® carboxylic acid, maximum excitation/emission
wavelength: 675nm/695 nm), a water-soluble and near infrared (NIR)
dye, was purchased from Bioacts (Incheon, Republic of Korea) and
activated to N-hydroxysuccinamide (NHS) groups using Dipyrrolidino
(N-succinimidyloxy) carbenium hexafluorophosphate (HSPyU) (St.
Louis, MO, USA) to conjugate to the amine group of peptide substrate.
Black hole quencher-3 (BHQ®-3, quenching range: 620–730 nm with
maximum absorption at 672 nm) coupled with NHS was obtained from
Bioresearch Technologies (Petaluma, CA, USA). The caspase-1 substrate
peptide (G-W-E-H-D-G-K) protected by tert-Butyloxycarbonyl (Boc),
tert-Butyl (tBu), and Trityl (Trt) groups in amine or carboxyl group of
each amino acid (H2N-G-W[Boc]-E[tBu]-H[Trt]-D[tBu]-G-K-OH,
Supplementary Fig. 1) was purchased from Peptron (Daejeon, Republic
of Korea). Caspase-1, caspase-3, caspase-8, and caspase-11 were pur-
chased from Enzo Life Science (Farmingdale, NY, USA). Caspase-1 in-
hibitor, Ac-YVAD-cmk, was obtained from Invivogen (San Diego, CA,
USA). Fetal bovine serum (FBS) and Roswell Park Memorial Institute
(RPMI) 1640 medium were purchased from Gibco (Carlsbad, CA, USA).
Dulbecco's modified Eagle's medium (DMEM) was purchased from
Thermo Scientific (Waltham, MA, USA). Lipopolysaccharides (LPS) and
adenosine triphosphate (ATP) were obtained from Sigma-Aldrich (St.
Louis, MO, USA). Dextran sodium sulfate (DSS) was purchased from MP
Biomedical (Santa Ana, CA, USA). 4′,6-diamidino-2-phenylindole di-
hydrochloride (DAPI) was purchased from Thermo Scientific.
2.2. Synthesis and characterization of caspase-1 activatable probe
The caspase-1 activatable (Cas-1) probe was synthesized by conjugating
Cy5.5 and BHQ-3 to caspase-1 substrate (G-W-E-H-D-G-K) (Supplementary
Fig. 1). First, BHQ-3-NHS was attached to an amine group of lysine (K) of
caspase-1 peptide substrate. Second, protecting groups were removed with
trifluoroacetic acid (TFA)/distilled water (DW)/Anisol (95:2.5:2.5). Third,
the Cy5.5-NHS was attached to the N-terminal of the caspase-1 substrate
peptide. Active caspase-1 recognizes WEHD sequence and cleaves site after
aspartate (D) [19]. The synthetic Cas-1 probe was characterized by ana-
lytical reverse phase-high performance liquid chromatography on C18
column (RP-HPLC, Agilent Tech, Santa Clara, CA, USA), UV–vis spectro-
fluorometer (F-7000 Fluorescence Spectrophotometer; Hitach, Tokyo,
Japan), and matrix-assisted laser desorption/ionization-time of flight mass
spectrometry (MALDI-TOF MS, Microflex LRF20, Bruker Daltonics,
Bremen, Germany) (Supplementary Fig. 2). The molecular weight
(2.255 kDa) of the synthetic probe was confirmed by mass spectrometry
and the purity (>90%) was analyzed by HPLC (Supplementary Figs. 2a
and b). The chemical structure of the Cas-1 probe was confirmed by proton
nuclear magnetic resonance spectroscopy (1H NMR, DD2 600MHz FT
NMR, Agilent Technologies, USA) using Cy5.5 (3mg/ml), BHQ-3 (3mg/
ml), and Cas-1 probe (6mg/ml) dissolved in DMSO‑d6 (Supplementary
Fig. 2c). To confirm the specificity of the Cas-1 probe, it was incubated for
2 h at 37 °C in the presence of 5 unit/ml of caspase-1, caspase-3, caspase-8,
caspase-11, or caspase-1 plus caspase-1 inhibitor, Ac-YVAD-cmk (20 μg/
ml). Fluorescence intensity was then measured in a caspase activation
buffer (50mM N-2-hydroxyethylpiperazine-N′-2-ethanesulfonic acid
(HEPES), pH 7.2, 50mM sodium chloride, 0.1% 3‐[(3‐Cholamidopropyl)
dimethylammonio]‐1‐propanesulfonate (CHAPS), 10mM ethylenediami-
netetraacetic acid (EDTA), 5% glycerol, and 10mM dithiothreitol) The Cas-
1 probe (2 μg/ml) was also incubated in the activation buffer containing
various concentration (0, 2.5, 5, 7.5, 10 unit/ml) of caspase-1 enzyme for
60min. The excitation wavelength was fixed at 675 nm and emission
wavelength measured from 676 nm to 800 nm for detection of fluorescence
radiation by a spectrofluorometer. A synthetic Cas-3 probe (Cy5.5-G-D-E-V-
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D-G-K-BHQ-3, substrate sequence underlined) was prepared as previously
described [20], and used as the control probe.
2.3. Cell culture, cytotoxicity, and hemocompatibility of caspase-1
activatable probe
Human monocyte cell line, THP-1 (Korean Cell Line Bank, Seoul,
Republic of Korea) was maintained in RPMI 1640 medium containing
10% (v/v) FBS, 1% (v/v) antibiotics/antimycotics (Welgene Inc,
Gyeongsan, Republic of Korea), and 10mM HEPES at 37 °C. Bone
marrow derived macrophages (BMDMs) were harvested from mice hind
leg bones. BMDMs were cultured for 7 d with macrophage colony-sti-
mulating factor (M-CSF, Peptron, Daejeon, Republic of Korea) in RPMI
1640 medium containing 10% (v/v) FBS and 1% (v/v) antibiotics/an-
timycotics. MC38 colon adenocarcinoma [21] cells were cultured in
DMEM with 10% FBS and 1% antibiotics/antimycotics. The cytotoxi-
city of the Cas-1 probe was evaluated by Cell Counting Kit-8 (CCK-8,
Sigma-Aldrich). In brief, BMDMs or THP-1 cells (1× 104 cells/well)
were seeded in 96-well microplate. Various concentrations of the Cas-1
probe (5, 10, 25, 50, and 100 μg/ml) were added to the cell culture and
incubated for 24 h. The absorbance of CCK-8 solution was observed at
450 nm with a plate reader (Molecular Devices, CA, USA). In order to
examine the hemocompatibility of the Cas-1 probe, we performed in
vitro hemolysis assay and in vivo hematological analysis. Hemolytic
activity of the synthetic probe was evaluated by assessing mouse red
blood cells (RBCs). Briefly, mouse blood was harvested in heparinized
tubes and RBCs were collected using Ficoll-paque PLUS density gra-
dient media (GE healthcare, Chicago, IL, USA) according to the man-
ufacturer's instruction. Fresh RBCs in suspension were incubated with
the Cas-1 probes at various concentrations (10, 20, 40, and 80 μM
which are equivalent to 22.5, 45.0, 90.0, and 180.0 μg/ml, respectively)
at room temperature for 1 h and centrifuged to collect the supernatants.
RBCs suspended in phosphate-buffered saline (PBS) and DW were used
as negative and positive control, respectively. The levels of released
hemoglobin in the supernatant solutions were assessed by measuring
absorbance at 540 nm using a microplate reader (Tecan, Mannedorf,
Switzerland). The hemolytic ratio was calculated as follows: % hemo-
lysis ratio=O.D.Test/O.D.Positive control x 100. The number of RBCs
collected by centrifugation was also counted by using hemocytometer
(Paul Marienfeld GmbH & Co. KG, Lauda-Königshofen, Germany). He-
matological changes were examined in mice injected with the Cas-1
probe. The synthetic probe (100 μg/100 μl of saline) was intravenously
injected via tail vein and whole blood was collected at 2 h after probe
injection to measure complete blood counts (CBC). Analysis of CBC was
performed using ADVIA 2012i Hematology System (Siemens Healthi-
neers, Erlangen, Germany).
2.4. In vitro imaging, flow cytometry, and enzyme-linked immune sorbent
assay (ELSIA)
BMDMs or THP-1 cells (2× 105 cells/dish) were seeded in 35mm
coverslip bottom dishes and cultured for overnight. Then, cells were
incubated in RPMI 1640 medium containing the Cas-1 or Cas-3 probe
(1.5 μg/ml). After 30min of incubation, LPS (1.5 μg/ml) was treated for
3 h followed by ATP (5mM) for 30min. Cells were then fixed in ab-
solute methanol and incubated with DAPI for nuclear staining for
10min. Cells were observed under a confocal microscope (Leica,
Wetzlar, Germany). For flow cytometric analysis, stimulated cells were
fixed with 4% paraformaldehyde and fluorescence intensities were ex-
amined on a FACS Fortessa II flow cytometer (BD Biosciences). Data
were analyzed using Flowjo software (Tree Star, Ashland, OR, USA).
Concentration of IL-1β in cell culture supernatants was also measured
by mouse IL-1β ELISA kits, according to manufacturer's instruction
(Biolegend, San Diego, CA, USA). The amount of IL-1β, IL-6, and tumor
necrosis factor (TNF)-α in mice sera were determined by Bio-Plex
ProTM cytokine assay system (Bio-Rad, Hercules, CA, USA).
2.5. Animal experiments
Mice (Orient Bio, Seoul, South Korea) were housed and maintained
in the specific pathogen-free facility at Seoul National University (SNU)
College of Medicine and Korea Institute of Science and Technology
(KIST). Animal experiments were performed after approval by SNU and
KIST IACUC (permission ID: SNU-180410-3, SNU-161223-1-2, SNU-
180410-3, KIST-2018-096). Caspase-1/11 knockout (KO) mice
(B6N.129S2-Casp1tm1Flv/J) were purchased from Jackson
Laboratories (Bar Harbor, ME, USA). These mice were bred with
homozygous mice and genotyped by polymerase chain reaction (PCR).
C57BL/6 mice were utilized for inflammation models and control ex-
periments as indicated. For endotoxin stimulation, mice were injected
with LPS (5 μg/mouse) and ATP (5 mg/mouse) in right footpad and
observed at the indicated time. Acute colitis was induced through the
oral intake of 3% DSS in fresh tap water ad libitum for the indicated
time. The mice were monitored daily and applied for imaging analysis.
For tumor models, athymic nude mice (six to eight week old, Nara
biotech, Seoul, Republic Korea) were subcutaneously injected with
MC38 cells (5× 106 cells/mouse) into the flank of mice or in-
travenously (5× 105 cells/mouse) via the lateral tail vein. Then, mice
were monitored every five days after tumor injection. For AD model, 5x
familial AD (5xFAD) mice (B6SJL-Tg [APPSwFlLon,
PS1*M146L*L286V] 6799Vas/J, Jackson Laboratories) were main-
tained by crossing the hemizygous transgenic mice with B6SJL F1 mice
(Jackson Laboratories) [22]. Transgenic mice were identified by PCR,
and non-transgenic littermates were used as controls. 5xFAD mice ex-
press both mutant human APP695, which harbors the Swedish muta-
tion (K670 N, M671L), Florida mutation (I716V), and London mutation
(V717I), and human PS1 with two FAD mutations (M146L and L286V).
T-maze and Y-maze were performed in the animal behavior laboratory
in SNU. T-maze was made of black acrylic plastic (each arm
30×15×7 cm and 7×7 cm center piece). At the start of the trials,
mice were placed into the start arm facing away from the goal arms,
after 30min habitation in an animal behavior testing room. Each mouse
could freely explore and to choose the left or right goal arm. Goal arms
were closed using the center piece after the tail cleared the goal arm.
After 30 s, the center piece was removed, and the mouse was moved
back into the start arm to choose again between the two open goal
arms. Two T-maze test trials were performed each day with at 1 h in-
tervals for 3 consecutive days, and scored as previously described [23].
If the mouse repeatedly chose the same goal arm in the same trial, it
scored 0, and if it selected a different goal arm, a score of 1 was given.
Y-maze consists of 3 equal arms (40×15×9 cm) using black acrylic
plastic [24]. After 10min habitation, mice were placed into the center
of Y-maze at the start of the trial. Mice could freely explore the three
arms for 8min. All movements were recorded by video camera and
alternation ratio, which were used to evaluate number of arm entries in
triplicates.
2.6. In vivo and ex vivo imaging
For sepsis model, the Cas-1 probe (100 μg/100 μl of saline/mouse)
was intravenously injected via tail vein at the indicated time after LPS
and ATP treatment. Live mice or lymph nodes collected from sacrificed
animals were imaged by an IVIS-Lumina Series III (Caliper Life Science,
Hopkinton, MA, USA) at the indicated time after the probe injection.
For DSS-induced colitis model, the Cas-1 probe was intravenously in-
jected at the indicated time after DSS treatment and live mice or col-
lected tissues from sacrificed mice were analyzed by IVIS-Lumina
system at the indicated time after Cas-1 probe injection. Mice trans-
planted with tumor cells were imaged by IVIS-Lumina or eXplore Optix
system (Advanced Research Technologies, Montreal, Canada) at 2 and
4 h after Cas-1 probe injection, respectively. In AD model imaging,
5xFAD mice (three to six months old) were analyzed each month. The
Cas-1 probe was intravenously injected and in vivo images were taken
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every 30min by eXplore Optix system starting at 2 h after probe in-
jection. Animals were also humanely sacrificed and collected brains and
lymph nodes were imaged by an IVIS-Lumina system. For non-invasive
imaging, animals were shaved before imaging process by IVIS-Lumina
system. In case of head imaging in AD model by eXplore Optix system,
we partially cut the skin to expose mouse skull. The fluorescence in-
tensity of region of interest (ROI) was calculated using the Living Image
software (for IVIS-Lumina, radiation efficiency= [photons/s]/[μW/
cm2]; PerkinElmer, Boston, MA, USA) or Analysis Workstation software
program (for eXplore Optix system, radiation efficiency= total pho-
tons/unit area; Advanced Research Technologies, Montreal, Canada), as
previously described [20,25]. Imaging analysis of all the mice and their
tissues to be compared was performed under the same settings and
conditions of the imaging systems. To define brain-draining lymph
nodes, 1 μl of solution containing Cy5.5 and 10% of Evans blue dye was
injected into ventricular zones of animals by stereotaxic surgery. 26-
gauge syringes (Hamilton, Nevada, USA) were used to inject into lateral
ventricles (coordinate from bregma: AP -0.46mm, ML±1.0mm, DV –
2.5 mm). In order to examine whether the Cas-1 probe without BHQ-3
could pass through the blood brain barrier (BBB), Cy5.5 dye conjugated
with G-W-E-H-D-G-K peptide (80 μg/mouse) was intravenously ad-
ministered to 3 month- and 6 month-aged 5xFAD mice and fluorescent
signals from their brains were measured by IVIS-Lumina system 2 h
after injection.
2.7. Tissue analysis
Collected tissues were processed by a homogenizer with cold lysis
buffer and caspase-1 activity of the tissue lysate was measured using
caspase-1 assay kit (Abcam, Cambridge, UK) in accordance with man-
ufacturer's instruction. For histological analysis, colons were fixed in
4% formalin and embedded in paraffin. The paraffin-embedded samples
were sectioned into 10 μm thick segments and stained with hematoxylin
and eosin (H&E) and scored as previously described [26].
2.8. Statistical analysis
The data was analyzed using Graph Pad Prism 5.01 software
(GraphPad Software, La Jolla, CA, USA). Statistical analysis was per-
formed using two-tailed Student's t-test with 95% confidence interval or
one-way analysis of variance (ANOVA) followed by Newman-Keuls t-
test for comparisons of values among different groups. Data are ex-
pressed as the mean ± standard deviation. A p value of< 0.05 was
considered statistically significant.
3. Results
3.1. Characterization of caspase-1-activatable fluorescent probe
Prior to the biological application of the synthetic Cas-1 probe, we
examined its stability and cellular toxicity. UV–vis absorbance spec-
trophotometry in a caspase activation buffer revealed a unique plasmon
resonance peak at 628 nm, whereas emission spectra showed that
fluorescence over 700 nm (emission peak of Cy5.5: 710 nm) was barely
detectable, indicating efficient quenching of emission fluorescence by
BHQ-3 (Supplementary Figs. 2d and e). Fluorescence was recovered
when the WEHD substrates were cleaved by caspase-1 (Fig. 1a and b,
and Supplementary Fig. 3). Quantitative measurement of emission
fluorescence in the 676–800 nm range of the Cas-1 probe showed linear
increase of signal intensity up to 10 unit/ml of caspase-1, whereas there
was no detectable increase in fluorescence signal from a Cas-3 probe
(DEVD as substrate) in the presence of caspase-1. Specific reactivity of
the synthetic probes was further confirmed by incubation with other
caspases, including caspase-3, 8, 11, or specific caspase-1 inhibitor, Ac-
YVAD-cmk (Fig. 1c). Time-dependent gradual increase of fluorescence
intensity was observed only in the samples incubated with caspase-1 (2
unit/ml), ensuring the specificity of the synthetic probes. In addition,
the signal intensities were reduced to baseline levels in the presence of a
caspase-1 inhibitor. Cellular toxicity test using phagocytic cells, THP-1
and BMDM, revealed negligible cell death up to 100 μg/ml of the
probes, indicating a clear biocompatibility within the probe con-
centration range (Supplementary Fig. 4a). We also evaluated the po-
tential hemolytic activity of the Cas-1 probe (Supplementary
Figs. 4b–d). The probe did not show any significant hemolytic activity
up to 80 μM (equivalent to 180.0 μg/ml) as assessed by spectro-
photometric measurement of released hemoglobin and by intact RBC
counting. Furthermore, in vivo injection of the Cas-1 probe (100 μg in
100 μl of saline) did not cause significant changes in CBC in general
(Supplementary Table 1). Even though there was a significant increase
of platelet counts and slight increase of lymphocyte counts, they re-
mained within normal range [27]. Therefore, this synthetic Cas-1 probe
is biocompatible and could be used for in vitro and in vivo application
without significant toxicity.
In order to investigate whether the synthetic probes could be trig-
gered by endogenous inflammasome activated caspase-1 within cellular
cytoplasm, THP-1 cells or BMDMs were pre-incubated with the Cas-1
probes and sequentially stimulated with exogenous LPS and ATP, well-
known activators of cellular inflammasome (Fig. 1d and e). Cells
treated with the inflammasome stimulators efficiently emitted Cy5.5-
specific fluorescence within the cytoplasm, as measured by confocal
fluorescent microscopy and flow cytometric analysis. These results in-
dicated that the synthetic probes can penetrate cellular plasma mem-
brane and are accessible to active caspase-1 within the cytoplasm. Ac-
tivation of cellular inflammasome was indirectly confirmed by secretion
of IL-1β into media in the stimulated phagocytic cells (Fig. 1f). In ad-
dition, activation of inflammasome was significantly inhibited in the
presence of a caspase-1 inhibitor, as assessed by reduced fluorescence
and IL-1β secretion from the stimulated phagocytic cells (Fig. 1d – f).
Cells loaded with Cas-3 probe did not emit significant fluorescence after
stimulation, indicating that signal emission by the Cas-1 probe upon
inflammasome activation is specific (Fig. 1d and e).
3.2. In vivo imaging of caspase-1 activation in acute inflammatory disorders
Next, we examined whether Cas-1 probes could be applied to detect
active caspase-1 in vivo. LPS and ATP solution containing 5 μg and 5mg,
respectively, in 50 μl of saline was injected into mice foot pads and the
probes were intravenously delivered at the indicated time after injec-
tion of the stimulators. Then, in vivo fluorescence was non-invasively
monitored by using IVIS-Lumina imaging system. When mice were in-
jected with the probe at 2 h after LPS and ATP stimulation, fluorescence
gradually intensified at foot pads and legs of the stimulated side, but
not of the unstimulated side, up to 2 h after inducing the reaction with
the (Supplementary Fig. 5a). At 2 h after injection of LPS and ATP, the
probe was administered. Radiation efficiencies, as well as relative ra-
diation, of the fluorescence of stimulated sites were significantly higher
than those of unstimulated foot pads of the same mouse at 30min after
probe injection (Fig. 2a and b). The mean radiation efficiency of sti-
mulated sites (mean ± S.D.: 2.0× 1010 ± 2.2×109) was four times
higher than that of unstimulated foot pads (5.0×109 ± 1.9×108) at
6 h after stimulation. In vivo fluorescence was barely detectable in the
stimulated foot pads of caspase-1/11 KO mice (Fig. 2a), indicating that
in vivo fluorescence is specifically generated by active caspase-1 via
inflammasome activation. We confirmed significant increase of caspase-
1 activity in tissue lysates of the stimulated foot pads of LPS/ATP-
treated mice at 6 h after stimulation (Fig. 2c). Since mice were mor-
ibund immediately after injection with LPS and ATP, we measured the
changes in rectal temperature as a systemic indicator of septic shock
(Fig. 2d). Rectal temperatures of stimulated mice sharply decreased to
~30.5 °C (normal temp.: ~36.0 °C) by 1 h, but recovered to normal
range at 1.5 h after LPS/ATP treatment. The stimulated mice fully re-
covered and were as active as unstimulated mice at 3 h after the
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stimulation. TNF-α and IL-6, inflammatory cytokines induced in sys-
temic shock, in sera of stimulated mice were also significantly elevated
at 2 h after LPS/ATP administration and declined to near the baseline
by 6 h (Fig. 2e). IL-1β levels, a cytokine released upon inflammasome
activation, in sera of stimulated mice were slightly, but significantly,
increased from 6 h after stimulation, suggesting a minor role of IL-1β in
symptomatic presentation during transient septic shock. Nevertheless,
kinetic changes of IL-1β concentration in sera of stimulated mice were
consistent with the fluorescence emission of the Cas-1 probe as mea-
sured by in vivo imaging, as well as caspase-1 activity, at the injection
sites of LPS and ATP. Since we also observed a gradual and specific
increase in fluorescence radiation along mice legs of the stimulated
side, but not of the unstimulated side of the same mouse
(Supplementary Fig. 5a), we suspected a lymphatic outflow of the ac-
tivated fluorescent probes, generated at the stimulated foot pad by in-
flammasome activation, to the draining lymph nodes. Therefore, po-
pliteal lymph nodes, draining lymph nodes of foot pad, were surgically
collected and applied for ex vivo fluorescence imaging. As expected, we
could consistently observe significantly elevated fluorescence in the
draining lymph nodes, of the stimulated foot pads from 2 h after sti-
mulation, when compared to those of non-stimulated foot pads from the
same mice (Fig. 2f and g). Ex vivo fluorescence was barely detectable in
neither stimulated nor non-stimulated draining lymph nodes in caspase-
1/11 KO mice even at 6 h after stimulation (Fig. 2f), reinforcing the
specificity of fluorescence emission by the Cas-1 probe via caspase-1
activation at the stimulated site. These results suggest that in vivo in-
flammasome activation by the exogenous stimulators can be efficiently
and spatiotemporally monitored by the activatable Cas-1 probe during
the acute phase of inflammation.
To further investigate the applicability of the synthetic probes as an
imaging agent in vivo, we selected the DSS-induced IBD model, in which
inflammasome activation plays a critical role in intestinal homeostasis
[28]. In vivo fluorescence in abdomens of mice supplied with 3% DSS-
containing water gradually increased up to 3 d after ingestion and
significantly higher (~two fold) fluorescence radiation efficiencies
(mean ± S.D.: 1.1× 1010 ± 1.2×109) were detectable at 2 d after
ingestion than those (6.3×109 ± 5.7× 108) of unstimulated mice
(Fig. 3a and b, and Supplementary Figs. 5b and 5c). Again, in vivo
fluorescence was not significant in abdomens of caspase-1/11 KO mice
up to 3 d of DSS administration. We observed significant weight loss,
starting at 6 d after DSS ingestion (Fig. 3c), and shrinkage of large in-
testines from 2 d after DSS treatment (Fig. 3d and e). Interestingly,
Fig. 1. In vitro characterization of the activatable Cas-1 fluorescence probe. (a) Diagram of Cas-1 probe design. (b) Relative fluorescence intensity emitted from the
Cas-1 or Cas-3 probe (2 μg/ml) after incubation with the indicated concentrations of caspase-1 for 60min at 37 °C. Upper, the corresponding NIR fluorescence images
of the Cas-1 probe treated with various concentrations of caspase-1; lower, linear regression of relative fluorescence intensities from duplicated experiments. The
excitation wavelength was fixed at 675 nm and emission wavelength was measured from 676 nm to 800 nm for detection of fluorescence radiation. Error bars:±
standard deviation (n=3). (c) Kinetic changes of fluorescence intensities emitted from the Cas-1 probe (2 μg/ml) in the presence of various caspases (5 unit/ml of
caspase-1, -3, -8, -11, and caspase-1 plus inhibitor) at the indicated incubation time. CNT, negative control without caspase. Cas: caspase, Inh: inhibitor. Error bars: +
standard deviation (n=3). (d) THP-1 cells and BMDMs were labeled with Cas-1 or Cas-3 probe (1.5 μg/ml) for 30 min, then, treated with LPS (1.5 μg/ml) for 3 h,
followed by ATP (5 mM) for 30 min. Cells were fixed, labeled with DAPI for nuclear staining, and observed under a confocal microscope. Confocal microscopic
images of unstimulated control (U.S.) and stimulated cells in the presence of caspase-1 inhibitor (LPS + ATP/Inh) are presented. Blue, nucleus; red, Cas-1 fluor-
escence. Bar, 20 μm. (e) Relative fluorescence intensities of THP-1 cells treated with LPS + ATP in the presence or absence of an inhibitor were assessed by flow
cytometry. Relative mean fluorescence intensities (MFI) from three independent experiments are plotted on the right panel. The mean value is indicated by the red
line. (f) Concentration of IL-1β in the cell culture supernatants was measured by ELISA after treating THP-1 cells with LPS ± ATP in the presence or absence of the
inhibitor for 24 h. Error bars: + standard deviation (n=2). (For interpretation of the references to colour in this figure legend, the reader is referred to the Web
version of this article.)
Y.J. Ko, et al. Biomaterials 226 (2020) 119543
5
elevated fluorescence intensity was initially prominent on the large
intestines in the ascending colon near the cecum and the rectum edge of
the descending colon, and then, gradually disseminated to transverse
parts (Fig. 3d). When we analyzed the histological changes in the sti-
mulated colon up to 3 d of DSS treatment, tissues from more fluorescent
sites presented pathological changes with mild epithelial erosions and
crypt atrophy, earlier than those from areas with lower radiation effi-
ciencies (Fig. 3f and g); however, the histopathological grades were
generally mild (histopathological scores: 1 out of 12) [26]. This sug-
gests a potential correlation of pathological changes with the degree of
inflammasome activation during the early stage of colonial inflamma-
tion. Gradual increase of fluorescence intensities was also observed in
intestine-draining mesenteric lymph nodes ex vivo during the acute
phase of inflammatory bowel disease (Fig. 3h).
3.3. In vivo imaging of caspase-1 activation in tumors and Alzheimer's
disease model
Since the role of inflammasome in various chronic inflammatory
disorders has recently been established [8,10,29], we next investigated
the potential association of caspase-1 activation with initiation and
progression of cancers and AD in mice models. First, we subcutaneously
injected MC38 colon cancer cells into nude mice and performed in vivo
imaging of caspase-1 activation using the Cas-1 probes. As shown in
Fig. 4a–c, fluorescence intensities and radiation areas gradually in-
creased at the injection sites, as the tumors grew. The tumor volumes
were generally correlated with the radiation efficiency of fluorescence
(Fig. 4b) and significant rise of fluorescence intensities at the tumor in-
jection sites were detectable from 5 d after implantation (Fig. 4c). Gra-
dual elevation of fluorescence in tumor-draining inguinal lymph nodes
was also observed in ex vivo imaging analysis and the radiation effi-
ciencies were significantly higher at 15 d after tumor injection when the
average tumor volume reached approximately 300mm3 (Fig. 4d and e).
Interestingly, we also observed significant increase of fluorescence in-
tensities in non-draining popliteal lymph nodes at 15 d after tumor in-
jection, suggesting a systemic increase of inflammasome activity in distal
lymph nodes (Fig. 4d and e, right panels). We also traced inflammasome
activation in a metastatic cancer model using the Cas-1 probe. Athymic
nude mice were intravenously injected with MC38 cancer cells, resulting
in pulmonary metastases of the cancer cells [30] (Fig. 4f and g). Non-
invasive in vivo imaging of upper backs of mice by eXplore Optix system
showed a gradual increase of fluorescence in four out of five mice at
15–20 d after injection with MC38 cells, although the differences in ra-
diation efficiencies were not statistically different between the experi-
mental groups (Fig. 4 f and g, upper panels). Nevertheless, we could
observe multiple tumor nodules in all the mice at 20 d MC38 cell injec-
tion with. Ex vivo imaging of lungs with metastatic tumors after Cas-1
probe administration clearly showed gradual rise of fluorescence in-
tensities throughout the lung tissues with significantly higher radiation at
20 d after tumor injection (Fig. 4f and g, lower panels).
Next, we investigated the potential association of caspase-1 activa-
tion with the initiation and progression of AD in mouse models [10]. T-
Fig. 2. In vivo imaging of caspase-1 activation after endotoxin stimulation. (a) LPS/ATP solution (5 μg and 5 mg/mouse, respectively) was injected into the indicated
foot pads (red arrowhead) of mice and the Cas-1 probes were intravenously delivered at the indicated time after LPS/ATP injection. Then, in vivo fluorescence in legs
of mice were monitored at 30min after the probe injection using IVIS-Lumina imaging system. (b) Comparison of fluorescence radiation in the right food pads (black
circles) stimulated with LPS/ATP with those of unstimulated sides (open circles) at the indicated time after stimulation (n=3). Absolute counts of radiation
efficiencies (left panel) and relative radiation (right panel) of the stimulated sites, normalized to unstimulated ones, are presented. Red line: mean. (c) Tissue lysates
from foot pads stimulated with LPS/ATP were analyzed by caspase-1 activity kit at the indicated time after stimulation (n=6). (d) Kinetic changes of rectal
temperature of mice injected with LPS/ATP at the foot pads (n=3). Error bar:± S.D. (e) Concentration of inflammatory cytokines (IL-1β, IL-6, and TNF-α) were
measured in sera of mice stimulated with LPS/ATP at the foot pads (n=3, duplicated). (f) Representative images of fluorescence radiation in popliteal lymph nodes
from mice stimulated with LPS/ATP at the foot pads. A pair of lymph nodes, one from stimulated leg (red arrowhead) and the other from unstimulated side, were
simultaneously analyzed at the indicated time after stimulation. (g) Quantitation of fluorescence intensities in (f) (n = 3). U.S., unstimulated. *, p < 0.05; **,
p < 0.01; ***, p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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maze and Y-maze tests were performed to evaluate working memory and
hippocampal-dependent spatial memory, respectively, in 2 to 5-month-
old wild type (WT) and 5XFAD mice (Fig. 5a). The spontaneous alter-
nation ratio observed in the T-maze and Y-maze tests were not sig-
nificantly different between WT and 5xFAD mice at 3–4 months of age,
as previously reported [31]. However, alternation ratios decreased in 5-
month-old 5xFAD mice when compared with WT, indicating significant
cognitive impairments from 5 months in 5xFAD mice. Caspase-1 activity
in the hippocampus was also significantly increased at 5–6 months of age
in 5xFAD mice, as measured by a commercially available caspase-1 en-
zyme assay kit of tissue lysates (Fig. 5b). These results suggest that in-
creased caspase-1 activity is dependent on age and is correlated with
cognitive impairments in AD mice. Next, we examined caspase-1 acti-
vation in AD mouse model by in vivo imaging after intravenous injection
of the Cas-1 probe. Fluorescence intensities on tops of heads of 5xFAD
mice gradually increased in an age-dependent manner when compared to
those of WT mice (Fig. 5c). Surprisingly, we found a significant increase
of fluorescence intensities from 3-month-old 5xFAD mice, when cogni-
tive impairments were not yet present. Ex vivo imaging consistently
showed that caspase-1 activation in the brains of 5xFAD mice was sig-
nificantly elevated from 3-month old 5xFAD mice, although fluorescence
radiation also gradually increased in WT mice in an age-dependent
manner (Fig. 5d, right upper panel). Relative radiation from the brains of
5xFAD mice at 3-months of old age was approximately 50% higher than
those of WT mice of the same age (Fig. 5d, right lower panel). Notably,
the strong fluorescence intensities were observed in central parts of the
brain (Fig. 5d), as previously reported [22]. Since we observed a gradual
increase of fluorescence in the brains of WT mice, we suspected diffusion
of the probe, potentially due to breakdown of the BBB in the brain as
mice age [32]. In order to determine whether diffusion of the florescent
probe through the BBB in the brain increases in an age-dependent
manner, we examined ex vivo fluorescence radiation of brains from WT
and 5xFAD mice at 3-month and 6-month-old age after intravenous in-
jection of Cy5.5-conjugated peptide only (without a quencher). As shown
in Fig. 5e and f, although the radiation efficiency was higher in 6-month-
old mice than 3-month-old mice, the difference of fluorescence radiation
was not significant between the brains of 3 and 6-month-old WT and
5xFAD mice. These findings indicate that caspase-1 is activated before
cognitive impairment in 5xFAD mice, although baseline diffusion of the
synthetic probe into brain tissues through the BBB also increases as mice
age, as previously reported [32].
Recently, it has also been reported that there is lymphatic outflow in
the brain into superficial cervical lymph nodes through deep cervical
lymph nodes located in the neck [33–35]. Since we observed consistent
caspase-1 activation in draining lymph nodes of inflammatory sites, we
speculated that activation of caspase-1 in AD model flows to brain-
draining lymph nodes in the necks of 5xFAD mice. To confirm cere-
brospinal fluid (CSF) flow routes to draining lymph nodes, we an-
esthetized mice and intracerebroventricularly injected a mixture of
Evans blue and free Cy5.5 fluorescent dye, and then imaged mandibular
and deep cervical lymph nodes in the neck at 15, 30, and 60min after
injection (Supplementary Fig. 6). Deep cervical lymph nodes were
stained with Evans blue and had fluorescent signal at 15min after dye
injection and the signals steadily increased over time. The mandibular
lymph nodes had slightly delayed dynamics, the fluorescence signal
within the nodes was detected in all mice at 30min after injection. A
Fig. 3. In vivo imaging of caspase-1 activation in inflammatory bowel disease model. (a) Mice ingested water containing 3% DSS ad libitum and the Cas-1 probes were
intravenously delivered at the indicated time (D2: day 2, D3: day 3). Then, in vivo fluorescence in the abdomens of mice was monitored by IVIS-Lumina imaging
system. (b) Comparison of fluorescence radiation in abdomens of mice fed with 3% DSS water at the indicated time after stimulation (n=3). Red line: mean. (c)
Kinetic changes of body weight in mice at the indicated days after administration of 3% DSS water (n=4). (d) Representative images of fluorescence radiation in
colons from mice fed with 3% DSS water. White lines indicate the site of cross-section for histopathological analysis. (e) Kinetic changes of colon lengths collected
from mice at the indicated days after administration of 3% DSS water (n=3). (f) Representative histological images (hematoxylin and eosin staining) of tissue
sections from sites I and II of colons indicated in (d). White bar, 200 μm. (g) Histopathological scores of site I (black circles) and II (open circles) of colon sections
from mice fed with 3% DSS water (n=4–6). (h) Representative images of fluorescence radiation in mesenteric lymph nodes from mice administered 3% DSS water.
U.S., unstimulated. *, p < 0.05; **, p < 0.01; ***, p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web
version of this article.)
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significant increase of fluorescence intensities at the lymph node sites in
the neck was observed even by non-invasive in vivo imaging of fluor-
escent dyes up to 60min after injection, suggesting rapid and sustained
lymphatic outflow of CSF to draining lymph nodes (Supplemented
Fig. 6a), as previously reported [35,36]. Therefore, we assessed whe-
ther fluorescence radiation in the neck of 5xFAD mice increases by non-
invasive imaging after injecting the Cas-1 probe. Indeed, we observed
significantly enhanced radiation in 5xFAD mice from four-months of
age, when compared to that of WT mice (Fig. 6a and c). We also con-
firmed that fluorescence intensities in deep cervical and superficial
cervical lymph nodes ex vivo gradually elevated over time in 5xFAD
mice (Fig. 6b and c). It is notable the relative fluorescence radiation was
significantly higher in superficial cervical lymph nodes from three-
months of age when compared to that of WT mice, whereas fluores-
cence intensities were significantly elevated in deep cervical lymph
nodes only at six-month age in AD model mice. Nevertheless, these
results indicate that non-invasive imaging of fluorescence radiation
from Cas-1 probes can be used to detect lymphatic outflow from in-
flamed brain lesions to the necks of 5xFAD mice as an indirect mea-
surement of brain inflammation (i.e. the activation of inflammasome).
4. Discussion
Recent advances in the use of “activatable” fluorescence probes in
optical imaging have demonstrated their wide applicability in in vitro
and in vivo monitoring of various biological activities and have fa-
cilitated biomedical applications in pre-clinical and clinical settings for
drug discovery, diagnosis, and therapeutic monitoring [37,38]. Acti-
vatable fluorescence probes comprise of a fluorophore and quencher
connected by a molecular linker which responds to specific biochemical
alterations and/or abnormalities. The activated probes then generate an
amplified fluorescence signal when the physical distance between the
fluorophore and quencher molecules increases in situ at the target site in
a live organism [37]. In previous studies, we and others have success-
fully developed activatable fluorescent probes that respond to diverse
biological enzymes, including cathepsins, matrix metalloproteases,
thrombin, and caspases, to target and monitor cancers, arthritis, and
ischemic lesions associated with that specific enzyme activity by non-
invasive in vivo imaging analysis [38–41].
Despite our expanding understanding of the biological significance
of inflammasome in various acute and chronic disorders, current
technologies to detect inflammasome activity have practical limitations
for in vivo application. Tools for monitoring inflammasome activation
have primarily relied on indirect and in vitro methods measuring the
levels of IL-1β or IL-18 secreted from inflamed cells or tissues [18].
Direct monitoring of caspase-1 activity, a hallmark executor of various
inflammasome machinery, generally requires cellular lysis during bio-
chemical analysis [18] or genetic modification of target cells for in vitro
or in vivo application [42,43]. All the recent technologies directly de-
tecting in vivo speck formation by ASC complexes upon inflammasome
Fig. 4. In vivo imaging of caspase-1 activation in cancer model. (a) MC38 colon cancer cells (5× 106 cells/mouse) were subcutaneously injected into the flank of
athymic nude mice and the Cas-1 probe was intravenously delivered at the indicated days after cancer cell injection. Then, in vivo fluorescence at tumor injection sites
of mice was monitored by using IVIS-Lumina imaging system. (b) Correlation of radiation efficiency with tumor volume at the injection sites. (c) Kinetic changes of
fluorescence intensities at the sites of tumors at the indicated time after cancer cell injection (n=4). (d) Representative images of fluorescence radiation in tumor-
draining inguinal lymph nodes and non-draining popliteal lymph nodes at the indicated time after cancer cell injection. (e) Radiation efficiencies of fluorescence
emitted from lymph nodes in (d) (n=6–8). Red line: mean. (f) Athymic nude mice were intravenously injected with MC38 cells (5×105 cells/mouse) via the lateral
tail vein and the Cas-1 probes were intravenously delivered at the indicated days after cancer cell injection. Then, fluorescence radiation of the upper backs (top
panels) or ex vivo lungs (middle and bottom panels) of mice was monitored by eXplore Optix system or IVIS-Lumina imaging system, respectively. (g) Radiation
efficiencies of fluorescence emitted from upper backs (top panel) or ex vivo lungs (bottom panel) in (f) (n = 4–5). CNT, normal mouse control. *, p < 0.05; **,
p < 0.01; ***, p < 0.001. (For interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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activation in a cellular level also require genetic modification of the
encoding gene [15–17]. In addition, methods using genetically mod-
ified ASC for speck formation as an inflammasome marker is in-
trinsically flawed due to the risk of non-specific aggregation without an
inflammatory stimulus if overexpressed [17] as well as potentially ad-
versely affecting the efficiency of caspase-1 activation via reduced re-
cruitment of caspase-1 [16]. Moreover, detection of speck formation
within cells or tissues upon stimulation requires knowing the exact site
of inflammation or scanning the inflamed areas of stimulated tissues to
identify cells containing ACS specks via microscopic imaging analysis.
Therefore, all the currently available technologies have substantial
limitations for direct in vivo imaging of intact organisms or tissues in a
spatiotemporal way.
In this study, we developed a synthetic probe, which emits fluor-
escence radiation upon activation of caspase-1 within cells or tissues.
Application of this novel probe for in vivo imaging of inflammasome
activation provides several advantages over other technologies. First,
the probe can penetrate cellular plasma membranes and readily access
cellular cytoplasms, thereby emitting NIR fluorescence upon cleavage
by active caspase-1 through inflammasome activation, as confirmed by
confocal microscopy and flow cytometry (Fig. 1d and e). Enhanced
membrane permeability of the peptide-based probe is possibly endowed
by covalent conjugation of hydrophobic quencher [44]. Although we
did not perform solubility test of the probe, we could assume relative
hydrophobicity of the probe based on RP-HPLC analysis using hydro-
phobic acetonitrile gradient (5% → 95%) as a mobile solvent
(Supplementary Fig. 2b). The probe was eluted at ~23min when the
solvent composition was 86% acetonitrile and 14% DW (including 0.1%
TFA), suggesting relative hydrophobicity. Since the probe contains a
peptide bridge comprised of four charged amino acids (Glu [E], His [H],
Asp [D], and Lys [K]), it may have some amphipathic characteristics.
This intrinsic property enables non-invasive in vivo imaging of fluor-
escence radiation from deep tissues, including the brain after penetra-
tion through the BBB, of a living organism. We observed gradual and
significant increase of in vivo fluorescence around areas where a pa-
thogenic insult was introduced in various inflammatory disease models,
including cancer and AD. In addition, the specific signal emission was
rapidly detectable from 30min after intravenous probe administration
and gradually rose up to 2 h of probe injection (Supplementary Fig. 5),
thereby increasing signal to noise ratio. Second, the radiation efficiency
and the fluorescence-emitting area of the activated Cas-1 probe corre-
late well with the degree of caspase-1 activity as measured by in vitro, ex
vivo, and in vivo imaging assays. This probe also allows us to specify the
inflamed site and the degree of inflammation in an organism and/or
Fig. 5. In vivo imaging of caspase-1 activation in Alzheimer's disease model. (a) WT (open circles) and 5xFAD (black circles) mice at the indicated months of age were
tested for working memory (T-maze task, top panel) and hippocampal-dependent spatial memory (Y-maze task, bottom panel) (n=10/group). Red line: mean. (b)
Tissue lysates of hippocampi from mice at the indicated months of age were analyzed by caspase-1 activity kit (n=6–9/group). Open circles, WT; black circles,
5xFAD mice. (c) Fluorescence radiation from heads of WT (open circles) or 5xFAD (black circles) mice at the indicated months of age was analyzed by eXplore Optix
system after Cas-1 probe intravenous injection. Representative fluorescence images of tops of mice heads (left panels) and quantitative comparison of total photons
per unit area (right panel) at the indicated age are presented. (d) Fluorescence efficiencies of brains collected from WT or 5xFAD mice at the indicated months of age
were analyzed by IVIS-Lumina imaging system after Cas-1 probe intravenous injection. Representative fluorescence images (left panels) of ex vivo brains collected
from mice at the indicated months of age, absolute counts of radiation efficiencies (right top panel), and relative radiation normalized to those of WT mice of the
same age (right panel) are presented. (e and f) Fluorescence efficiency of probes in brains collected from mice at the indicated age was analyzed by IVIS-Lumina
imaging system after intravenous injection with Cy5.5-peptide conjugate without BHQ quencher (n = 3/group). *, p < 0.05; **, p < 0.01; ***, p < 0.001. (For
interpretation of the references to colour in this figure legend, the reader is referred to the Web version of this article.)
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tissue by microscopic imaging analysis. For example, ex vivo imaging of
colons in mice fed with DSS can specifically identify the inflammatory
regions in which the histopathologic changes were more advanced even
in the early stage of inflammatory bowel condition, as assessed by
fluorescence intensities, (Fig. 3d~ g). The intensities and area of
fluorescence radiation can also help indirectly infer the size and dis-
tribution of cancer nodules (Fig. 4) and pathogenic inflammation in the
brain that are possible sites of amyloid plaque deposition in the deep
cortex, subiculum, and hippocampus during the early stage of AD pa-
thogenesis (Fig. 5) [22]. Furthermore, the fluorescent probe can also
label draining lymph nodes of inflamed sites, potentially via lymphatic
outflow of free fluorescence probes or probe-associated cellular entities
formed by pyroptosis. This property of Cas-1 probe could contribute to
enhanced fluorescence by retaining the fluorescent probes near the
inflammatory site and assist to localize the original source of in-
flammatory site by non-invasive in vivo imaging of draining lymph
nodes, as we observed in various inflammatory conditions including AD
(Fig. 6). Third, the synthetic probe is biocompatible and barely toxic to
the cells as confirmed by cytotoxicity test and hemolytic activity assay.
It did not significantly affect cellular viability up to 100 μg/ml and did
not show hemolytic activity up to 180.0 μg/ml (Supplementary Fig. 4).
Moreover, intravenous injection of the probe (100 μg) in mice did not
cause significant hematological changes (Supplementary Table 1). The
Cas-1 probe is likely rapidly secreted out through the kidney within a
few hours after intravenous administration. Among the major organs of
normal mice including liver, lung, spleen, and heart, we observed
strong fluorescence radiation only in the kidney at 3 h after probe in-
jection, which disappeared at 24 and 72 h (Supplementary Fig. 7). Low
cellular toxicity and quick elimination within a live organism confer
significant benefit for in vivo pre-clinical and clinical application.
In summary, we developed an activatable fluorescence probe that
specifically responds to caspase-1 activity, a hallmark executor of in-
flammasome activation. This novel caspase-1 probe is efficiently de-
livered into cells and specifically emits fluorescence upon caspase-1
activation in in vitro and in vivo inflammatory conditions. Non-invasive
in vivo imaging of caspase-1 activation enabled us to detect early stage
of various inflammatory conditions that are initiated by inflammasome
before symptomatic presentations. Particularly, in vivo inflammation of
intestine in IBD model or brain in AD model is detected 4 d and 2
months earlier, respectively, before symptomatic signs. In addition,
efficient visualization of inflammasome activity made it possible to
pinpoint inflammatory sites where the associated pathologic changes
occur. Therefore, efficient and rapid detection of caspase-1 activity in
vivo can revolutionize the current paradigm for diagnosis and ther-
apeutics in various inflammatory disorders associated with inflamma-
some activation.
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normalization with those of WT mice of the same age was performed using the data from (b). Neck, n= 11–14/group; scLN, n = 21–30/group; dcLN, 11–14/group.
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